• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Pharmaceutical Focus: A Look at Combination Products

    The Printed World: Additive Manufacturing in Medtech

    The Lost Year: 2020 Year in Review

    Extrusion Evolution

    Little Big Parts: Micromolding Under the Microscope
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    Cretex Companies CEO Steps Down

    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread

    Endoscopic Hemostasis Devices Market Valued at $730 Million

    Henry Schein Buys Majority Interest in Prism Medical Products

    Boston Scientific's Vercise Genus DBS Earns FDA Approval
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Pharmaceutical Focus: A Look at Combination Products

    The Printed World: Additive Manufacturing in Medtech

    The Lost Year: 2020 Year in Review

    Extrusion Evolution

    Little Big Parts: Micromolding Under the Microscope
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Fixing Face Mask Form and Function

    The Heart of the Matter: Trends in Cardiology

    Virtually the Same? The Challenges of Online Conferences

    Digital Health Delivers During a Year for the Ages

    Advanced Technology for Staking and Swaging Medical Plastics
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    maxon

    K-Tube Technologies

    Spectrum Plastics Group

    Medbio LLC

    Creganna Medical, part of TE Connectivity
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Meeting Critical Ventilator Product Requirements Amid Pandemic

    Impact of COVID-19 on the Medtech Supply Chain

    Finding the Upside to a Challenging Year

    Preparing Your Design Controls for FDA Approval

    A 'Trial and Error' Approach to Micromolded Parts
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    FUTEK Advanced Sensor Technology Inc.

    Creganna Medical, part of TE Connectivity

    MW Life Sciences

    PTI Engineered Plastics Inc.

    Element
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Features

    Shock to the System: An Examination of Neurostim Technologies

    Targeted electrical nerve stimulation technology can aid in chronic disease management by improving on current treatment methods.

    Shock to the System: An Examination of Neurostim Technologies
    The NSS-2 BRIDGE device placed on the ear. Image courtesy of Innovative Health Solutions.
    Shock to the System: An Examination of Neurostim Technologies
    An exploded view of an implantable pulse generator, showing vertically integrated components. Image courtesy of Integer Holdings Corp.
    Shock to the System: An Examination of Neurostim Technologies
    SetPoint Medical MicroRegulator. Image courtesy of SetPoint Medical.
    Shock to the System: An Examination of Neurostim Technologies
    The NSS-2 BRIDGE device assembled. Image courtesy of Innovative Health Solutions.
    Shock to the System: An Examination of Neurostim Technologies
    A full implantable pulse generator system. Image courtesy of Integer Holdings Corp.
    Related CONTENT
    • Medtech Matters: Surgeons Scrubbing In Virtually
    • Medtech Matters: Talking Robotic Surgery with Zimmer Biomet
    • Greenlight Guru and Nelson Labs Partner
    • Medtech Veteran Joins VivaLNK Board
    • New Global Headquarters for Freudenberg Medical
    Sam Brusco, Associate Editor09.09.19
    Alteration of nerve activity through targeted electrical stimulation has been practiced for millennia. There are records as early as 46 A.D. of electrical torpedo fish—or electric rays—being applied directly to a painful area to induce relief. The resulting shock briefly stuns the nervous system, provoking immediate and residual numbness. As such, electric rays became the first transcutaneous electrical nerve stimulation (TENS) devices and were often used to treat gouty arthritis.

    The practice has understandably since evolved, and researchers worldwide are investigating altering nerve activity in specific nerves or neurological sites in the body. Applying small, electrical stimuli to specific nerves has been found to have enormous potential in treating various conditions from epilepsy to mental health to heart disease. This method of treating chronic conditions is known as neuromodulation or neurostimulation (neurostim). Eventually, neurostim devices were implanted in the body at specific sites for more direct application of electrical pulses.

    “Although originally invasive in nature, neurostimulation devices have evolved from invasive procedures to external electrical stimulators, such as vagus nerve stimulation (VNS) devices to transcutaneous vagus nerve stimulation (TVNS) devices,” said David Novotny, general manager and global head of medical device and diagnostic research for ICON plc, a Dublin, Ireland-based global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organizations. “Moreover, engineers have focused on reducing battery size in implantable devices, making implantable stimulators a more attractive option for patients concerned with cosmetic appearances.”

    The core neurostimulation therapies of spinal cord stimulation, deep brain stimulation, and vagus nerve stimulation have been continuously advancing. For example, spinal cord stimulation was initially centered on hardware innovation and the focus has shifted to waveform innovations, strategies that stimulate the spinal cord by a different mechanism of action like high-frequency or burst stimulation, which consists of closely packed high-frequency impulses, followed by a quiescent period. Other advancements include systems that automatically adjust treatment and shrinking the devices for the patient’s benefit.

    “The introduction of more advanced waveforms and stimulation frequencies offers greater programming flexibility to meet patients’ needs,” commented Brian LaPrade, product management director, cardiac rhythm management & neuromodulation at Integer Holdings Corp., a Plano, Texas-based medical device outsource manufacturer. “We also see the development of closed-loop systems that enable devices to automatically adjust based on ‘detected’ responses, miniaturization of devices to improve patient comfort and reduce procedure invasiveness (including use of externally powered ‘injectable’ devices), and a shift to Bluetooth communication between the implanted device and externals.”

    The neurostim market has flourished as proof of these devices’ effectiveness has grown. Neurostim’s scientific and technological advancement continues due to the increase in the geriatric population and the rise of the devices’ safety and efficacy. Pamela Kennedy, R.N.—ICON plc’s executive director, business development, medical device and diagnostic research—outlined the myriad external and internal neurostim technologies and how they are impacting various therapeutic areas:

    External neurostim devices:
    • Transcutaneous electrical nerve stimulation (TENS)—chronic neuropathic pain, fibromyalgia
    • Transcutaneous vagus nerve stimulation (TVNS)—anxiety, depression, autism, aging
    • Transcranial magnetic stimulation (TMS)—depression, ADHD
    • Respiratory electrical stimulation (RES)—Improvement of respiratory function after spinal cord injury
    Internal neurostim (implants):
    • Spinal cord stimulation (SCS)—pain management, spasticity
    • Deep brain stimulation (DBS)—Parkinson’s, depression, epilepsy
    • Vagus nerve stimulation (VNS)—epilepsy, depression
    • Sacral nerve stimulation (SNS)—urinary incontinence, constipation
    • Gastric electrical stimulation (GES)—obesity, gastroparesis

    “Neurostimulation technology offers potential to improve upon traditional treatment options in the areas of epilepsy, Parkinson’s, depression, sleep apnea, dystonia (spasticity), pain management, obesity/gastric, migraine, and heart disease,” Kennedy explained. “Also, neurostimulation devices are improving upon traditional treatments for these conditions by offering an affordable and non-invasive treatment option in a financially overburdened healthcare system. Moreover, in the case of Parkinson’s disease, epilepsy, and urinary incontinence conditions, neurostimulation offers hope for patients that previously had little to no treatment options and poor quality of life.”

    First used to treat pain in 1967, SCS delivers mild electrical stimulation to the nerves along the spinal column, modifying nerve activity to minimize pain signals to the brain. The therapy began routine use in the 1980s, and the FDA first approved SCS in 1989 to relieve chronic pain from nerve damage in the trunk, arms, or legs. According to the International Neuromodulation Society, SCS therapy accounts for about 70 percent of all neuromodulation treatments, and about 34,000 patients undergo SCS implants each year worldwide.

    “While vagus nerve stimulation and deep brain stimulation led the industry in the mid-1990s, spinal cord stimulation continues to hold the largest market share today,” Kennedy noted.

    SCS treats pain that is neuropathic in origin—meaning it arises from nerve damage and doesn’t serve a protective purpose. The damage usually occurs as a result of accident, injury, or disease and SCS therapy is most commonly indicated for the treatment of neuropathic back and leg pain. Since the 80s, SCS therapy has advanced in ways that tailor the treatment to a patient’s individual needs. Newer lead designs allow more precise control of the electrical field, and increasingly sophisticated devices offer a myriad of stimulation parameters. Some SCS devices can even achieve pain reduction without evoking perceptible sensations.

    Medical device makers featuring a cardiac rhythm management portfolio—Medtronic, Abbott Laboratories, and Boston Scientific, for example—typically also offer SCS and other neurostim devices because both devices’ mechanisms of action similarly involve the delivery of electrical pulses to a specific site via a lead. The latest SCS technologies incorporate peripheral tools to assist in recording/analyzing the treatment and/or target novel neurological areas to enhance therapy. Medtronic claims its Intellis SCS platform with AdaptiveStim is the smallest fully implantable spinal cord neurostimulator and includes a clinician programmer and reporting via tablet to track a patient’s progress. Abbott’s Proclaim DRG targets the dorsal root ganglion (DRG) to stimulate primary sensory neurons, a processing point of sensory information. Boston Scientific claims its Spectra WaveWriter SCS system is the first designed to personalize pain relief through combination therapy and the simplicity of waveform automation.

    Rather than blocking signals to the brain, DBS involves implanting electrodes within certain areas of the brain. These electrodes produce electrical impulses that regulate abnormal impulses or affect specific cells and chemicals within the brain. The amount of DBS is controlled by a pacemaker-like device placed under the skin in the upper chest, and a wire traveling under the skin connects it to the electrodes in the brain.

    DBS is currently approved by the FDA to treat dystonia (a movement disorder), epilepsy, essential tremor, obsessive-compulsive disorder, and Parkinson’s disease. It is also undergoing evaluation as a potential treatment for a variety of conditions: addiction, chronic pain, cluster headache, dementia, major depressive disorder, Huntington’s disease, multiple sclerosis, stroke recovery, Tourette syndrome, and traumatic brain injury. As the procedure to install a DBS system involves both brain surgery and chest wall surgery, the treatment is reserved for people who aren’t able to control their symptoms with medications.

    Modern DBS systems also feature enhancements that improve the clinician and patient interaction with the device. Medtronic’s Activa DBS portfolio contains the first rechargeable device and has 15-year longevity. Abbott’s Infinity DBS system is controlled with an Apple iPad mini mobile digital device so the doctor can adjust the setting for personalized, discreet therapy management. Boston Scientific claims its Vercise DBS system was the first engineered for precise neural targeting to customize therapy for patients with Parkinson’s disease, primary and secondary dystonia, and essential tremor. Its Vercise Gevia DBS system was approved for MRI labeling toward the end of August.

    New therapeutic areas have been uncovered as research in neurostim continues. For example, continuous positive airway pressure (CPAP) is the usual treatment option for obstructive sleep apnea (OSA). Many people can’t tolerate the cumbersome nightly therapy. The FDA approved Inspire Upper Airway Stimulation in 2014 to treat OSA in those that can’t tolerate CPAP, and it has found success. Further, VNS, which has historically been used to treat epilepsy, has found success in curbing obesity as well.

    “Neurostimulation has been leveraged to treat sleep apnea by stimulating the activity of the hypoglossal nerve, which supports the activity of the tongue,” said Novotny. “In sleep apnea patients, because the tongue relaxes and collapses into the upper airway during sleep, the device stimulates the tongue to help prevent obstructions in the upper airway. Neurostimulation has also been shown to help treat obesity by stimulating the vagus nerve, which serves as the signaling connection between the stomach and the brain.”

    Neurostim technology has the potential to be an aid in stemming opioid abuse, as well. The symptoms of opioid withdrawal can be incredibly distressing, come on quickly, and are one of the main reasons patients with physical dependence on the drugs have so much trouble stopping them. Early symptoms usually begin in the first 24 hours depending on the intensity of the patient’s physical dependence on the drug and include anxiety, cramping, muscle aches, restlessness, sweating, tears, and a runny nose. Later, more intense symptoms like diarrhea, abdominal cramping, nausea and vomiting, rapid heartbeat, and hypertension set in after the first day.

    Innovative Health Solutions’ (IHS) NSS-2 BRIDGE is a percutaneous nerve field stimulator device system that can be used as an aid to reduce symptoms of opioid withdrawal through application to branches of specific cranial nerves, as well as branches of the occipital nerves identified via transillumination. NSS-2 BRIDGE received FDA clearance in November 2017 and has since been used by doctors and treatment centers at the local and state level to assist thousands of people suffering from opioid withdrawal symptoms.

    “The NSS-2 BRIDGE goes behind the patient’s ear and includes micro-needle arrays that percutaneously implant in and around the ear and send gentle electrical impulses to branches of the nerves that lead to central brain regions involved in symptoms of withdrawal, particularly the amygdala and spinal cord,” explained an IHS spokesperson. “Research study results show an 84.6 percent reduction of withdrawal symptoms in as little as 60 minutes.”

    The device helps to alleviate the opioid withdrawal symptoms of nausea, diarrhea, vomiting, abdominal pain, anxiety, and restlessness. Relieving these symptoms in as little as 60 minutes can go a long way to aid in a long-term recovery plan from opioid withdrawal.

    “Greater early decreases in withdrawal scores have been shown to significantly correlate with long-term treatment success,” the IHS spokesperson went on.

    IHS also gained FDA clearance in June for the first treatment indicated to reduce pain in children dealing with functional abdominal pain associated with irritable bowel syndrome (IBS). “There are currently no other approved therapies for IBS in children. Currently approved medications for IBS in adults all work at the level of the gut and are often used off-label in children, despite the risk of serious side effects,” the company spokesperson explained. “Also, the intensity of withdrawal symptoms has been correlated with treatment drop-out. Therefore, treatment with NSS-2 BRIDGE is likely to enhance long-term recovery, regardless of the type of medication-assisted therapy used. It allows patients to overcome a major hurdle and is meant to enhance long-term recovery.”

    IB-Stim targets brain regions involved in pain processing, unlike traditional therapies for IBS that target the gut. IB-Stim is also nonsurgical, targeting central brain areas through stimulation of cranial nerves in the ear. Prior to FDA clearance, the device underwent a double-blind, randomized, controlled trial that included 104 patients aged 11-18 with functional abdominal pain disorders, measuring the effects of IB-Stim compared to placebo on several pain aspects including worst pain and the pain-frequency-severity-duration composite score. It also measured patients’ overall symptom improvement based on the Symptom Response Scale. The company’s sub-analysis of IBS subjects showed before IB-Stim treatment, 70 percent of patients failed to improve with four medications trialed. However, patients treated with IB-Stim had an 81 percent improvement in global symptoms with no serious adverse events, and minimal to no side effects.

    “IB-Stim treats functional abdominal pain associated with IBS in patients ages 11-18,” the company spokesperson commented. “The IB-Stim is a non-surgical device that is placed behind the patient’s ear during an outpatient visit and works by sending gentle electrical impulses into cranial nerve bundles located in the ear. This stimulation targets brain areas involved in processing pain and aids in the reduction of functional abdominal pain associated with IBS.”

    Bioelectronic medicine merges molecular medicine, neuroscience, engineering, and computing to develop devices to diagnose and treat diseases, and represents a potential revolution in disease management. The discipline arose from discoveries of mechanisms for neural control of biological processes that underlie disease, and development of technologies to therapeutically modulate those specific neural circuits using electrons in place of drugs. A bioelectronic medical device uses precise electrical pulses like a neurostim technology, but the pulses are used to activate systemic responses for the treatment of certain chronic diseases.

    “Bioelectronic medicine differs from traditional neuromodulation therapies by addressing the underlying pathophysiology to provide a potential cure for the disease versus simply masking the symptoms of disease,” explained Ankit Shah, senior director of commercialization and marketing for SetPoint Medical, a Valencia, Calif.-based bioelectronic medicine company that is dedicated to treating patients with chronic autoimmune diseases.

    SetPoint Medical’s unique approach to bioelectronic medicine aims to return the body to its natural immunological “set point” by using vagus nerve stimulation to restore immunological homeostasis. It does so through targeted electrical pulses to the vagus nerve to trigger the inflammatory reflex, which regulates and restores balance to the immune system. The vagus nerve also innervates the spleen, which is also responsible for responding to infection and inflammation. Activating the inflammatory reflex alters the phenotype of inflammatory cells in the spleen, reducing the amount of circulating cytokines and dampening systemic inflammation.

    Current vagus nerve stimulating devices require two incisions to implant a large pulse generator in the chest with a wired lead tunneled to the neck. SetPoint’s device, however, is a miniaturized, rechargeable system with an integrated electrode and no lead, so it can be implanted with a single incision, minimally invasive procedure on the nerve. This reduction in the implant’s footprint substantially benefits patients, delivering a proprietary pulse pattern for autoimmune disease treatment.

    “We have conducted multiple clinical studies to better understand the safety and effectiveness of bioelectronic medicine as a potential alternative to treatment of chronic, inflammation-mediated autoimmune diseases,” said Shah. “We are initially focused on the development of our device for the treatment of rheumatoid arthritis (RA) as a lead indication. Our device also has promising data for Crohn’s disease as well as multiple sclerosis (MS) in various stages of development.”

    RA is a challenging condition to treat because according to SetPoint, 30-40 percent of RA patients don’t adequately respond to or are intolerant of biologic therapies—those therapies already have potentially serious side effects, and patient compliance is a serious issue. These biologic therapies also financially burden the healthcare system because some of the highest revenue grossing drugs are indicated for patients with RA and other autoimmune diseases.

    “There is a major unmet need for novel treatment options for autoimmune diseases that are more efficacious, less immunosuppressive, and more cost-effective than currently approved therapies,” noted Shah.

    The company recently posted positive results from its U.S. pilot IDE study evaluating its bioelectronic medicine device for RA treatment. SetPoint Medical’s bioelectronic medicine was found to be well-tolerated with no device-related adverse events through 12 weeks. Five of the 10 active stimulation patients who had failed multiple biologic and targeted synthetic therapies had clinically meaningful improvement in RA signs and symptoms as measured by Disease Activity Score (DAS28-CRP) and Clinical Disease Activity Index (DCAI), two validated disease measurement instruments. Two of those patients even achieved DAS28-CRP remission.

    “Unlike traditional biologic therapies which aim to eliminate the bioavailability of a single pro-inflammatory cytokine, SetPoint’s bioelectronic medicine approach has been shown to suppress a range of inflammatory cytokines by 30-70 percent without eliminating the bioavailability of any single cytokine,” said Shah. “In doing so, inflammation can be reduced without causing significant immunosuppression, which is a major risk factor for serious side effects like systemic infections associated with almost all currently available therapies for RA.”

    In addition to clinical studies in RA and Crohn’s disease, SetPoint is currently studying the potential of its bioelectronic medicine for MS. Preclinical research is ongoing, and according to the company, results show promising early signals of efficacy in animal MS models.

    Neurostim OEMs, like any other medical device maker, aim to bring their innovative therapies to market as fast and as cost-effectively as possible. When this challenge involves more capacity and cost than the device maker has, they might consider turning to a partner with expertise in building neurostim technologies. These specialized firms have made the investments in engineering know-how, technology platforms, quality systems, and manufacturing capacity required to build a Class III medical device system like an implantable neurostim device. OEM partners can leverage this strength to supplement and accelerate their development activities.

    “We offer one of the broadest portfolios of neurostimulation technologies in the medical device outsource market,” said LaPrade. “This includes full finished device capability for implantable pulse generators (IPGs), implantable leads and external devices (e.g., chargers); critical IPG components, including rechargeable Li-ion and non-rechargeable battery technology, hermetic feedthroughs, formed enclosures, header assemblies, and machined components; and critical lead components, including precious metal electrodes, single wire and multi filar coiled lead wires and molded assemblies.”

    Because medical device outsource partners like Integer have engineers with specific knowledge and experience with neurostim products, they can uniquely assist OEMs in refining product concepts and translating requirements into designs and specifications. “During this upfront design phase, our engineers offer a consultative approach and often provide our customers with recommendations for improvements in size, form factor, manufacturability, reliability, performance, and cost,” LaPrade explained.

    The faster and more effectively a neurostim device can be built, the quicker patients can utilize this therapy poised to serve as effective treatment for disease states throughout the body.

    “We offer comprehensive development services for finished systems, including mechanical, electronics, software, firmware, and process development,” said LaPrade. “We have developed more than 40 IPG systems throughout our 40+ year history. During this time, we have also created a portfolio of platform technology modules that we customize, which significantly reduces the time and risk of development. As a vertically integrated supplier, we can offer custom component (e.g., battery) design and development services.”  
    Related Searches
    • devices
    • class iii
    • design
    • epilepsy
    Related Knowledge Center
    • Contract Manufacturing
    • Electronics
    • Neurological
    Suggested For You
    Medtech Matters: Medtronic Medtech Matters: Medtronic's Robotic Surgery Status
    Medtech Makers: Material Science for Micromolding Medtech Makers: Material Science for Micromolding
    Medtech Matters: Surgeons Scrubbing In Virtually Medtech Matters: Surgeons Scrubbing In Virtually
    Medtech Matters: Talking Robotic Surgery with Zimmer Biomet Medtech Matters: Talking Robotic Surgery with Zimmer Biomet
    Greenlight Guru and Nelson Labs Partner Greenlight Guru and Nelson Labs Partner
    Medtech Veteran Joins VivaLNK Board Medtech Veteran Joins VivaLNK Board
    New Global Headquarters for Freudenberg Medical New Global Headquarters for Freudenberg Medical
    Impact of COVID-19 on the Medtech Supply Chain Impact of COVID-19 on the Medtech Supply Chain
    Mike on Medtech: Communicating with the FDA Mike on Medtech: Communicating with the FDA
    Finding the Upside to a Challenging Year Finding the Upside to a Challenging Year
    BellaSeno Establishes High-Throughput Additive Manufacturing Facility for Resorbable Implants BellaSeno Establishes High-Throughput Additive Manufacturing Facility for Resorbable Implants
    Medtech Matters: Talking Medtech with Joe Mullings Medtech Matters: Talking Medtech with Joe Mullings
    Expert Roundup: Achieving Success in the 2021 Medical Device Landscape Expert Roundup: Achieving Success in the 2021 Medical Device Landscape
    Olympus Corporation to Acquire Veran Medical Technologies Olympus Corporation to Acquire Veran Medical Technologies
    Setting the Standard: Protective Nanocoatings for Today Setting the Standard: Protective Nanocoatings for Today's Medtech

    Related Features

    • Contract Manufacturing
      Automatic Pilot: Automation Provides Solutions for Assembly Challenges

      Automatic Pilot: Automation Provides Solutions for Assembly Challenges

      Assembly and automation experts discuss the market forces and technology trends affecting the industries.
      Sam Brusco, Associate Editor 09.01.20

    • Electronics
      Mission Complete: Successfully Sourcing Custom Medical Electronics

      Mission Complete: Successfully Sourcing Custom Medical Electronics

      Healthcare’s digital transformation is driving demand for custom medical electronics that deliver total solutions.
      Michael Barbella, Managing Editor 09.01.20

    • Contract Manufacturing
      Contract Partners: A Discussion of Full Service Outsourcing

      Contract Partners: A Discussion of Full Service Outsourcing

      Today’s outsourcing providers are more than just “hired help”; they serve as an extension of an OEM’s capabilities.
      Sean Fenske, Editor-in-Chief 05.01.20


    • Electronics
      Medtech Connects with Electronic Manufacturing Solutions

      Medtech Connects with Electronic Manufacturing Solutions

      IoT, data collection, wearability, connectivity, and miniaturization lead as the demands medtech has of its electronics-centric suppliers.
      Mark Crawford, Contributing Writer 01.29.20

    • Contract Manufacturing | Materials | R&D & Design
      Delivering the Goods: The Evolving World of Combination Products

      Delivering the Goods: The Evolving World of Combination Products

      This extremely diverse market fosters relationships between medical device and pharmaceutical companies.
      Sam Brusco, Associate Editor 11.04.19

    • Contract Manufacturing
      Assembling with Reliability and Repeatability Through Automation

      Assembling with Reliability and Repeatability Through Automation

      Progress in assembly and automation technologies enable manufacturers to leverage capabilities such as Industry 4.0 and IoT for medical device fabrication.
      Mark Crawford, Contributing Writer 09.09.19


    • Cardiovascular | Contract Manufacturing | Diagnostics | Digital Health | Electronics | Neurological | Patient Monitoring | R&D & Design
      Customized Connections: A Discussion on Custom Electronics

      Customized Connections: A Discussion on Custom Electronics

      Demand for more complex, traceable, integrated solutions are driving innovation in the fast-changing medical electronics market.
      Michael Barbella, Managing Editor 09.09.19

    • Contract Manufacturing
      An Extension of Reach: A Discussion of Full-Service Outsourcing

      An Extension of Reach: A Discussion of Full-Service Outsourcing

      OEMs recognize outsourcing service providers as opportunities for cutting costs and improving time to market while maintaining quality of product.
      Sean Fenske, Editor-in-Chief 05.01.19

    • Cardiovascular | Contract Manufacturing | Diagnostics | Molding | Surgical
      Once or Again? Single-Use Products Are Gaining Attention

      Once or Again? Single-Use Products Are Gaining Attention

      Bolstered by recent study findings and their infection control prowess, the single-use device market is primed for growth.
      Michael Barbella, Managing Editor 04.03.19


    • Contract Manufacturing | Digital Health | Electronics | Patient Monitoring
      Electrifying Healthcare: A Look at Electronics Manufacturing Services for Medtech

      Electrifying Healthcare: A Look at Electronics Manufacturing Services for Medtech

      Demand for miniaturization and low power challenges EMS providers serving the medtech industry.
      Mark Crawford, Contributing Writer 01.30.19

    • 3D/Additive Manufacturing | Contract Manufacturing | Machining & Laser Processing | Materials
      Smooth Operator: Addressing Machining

      Smooth Operator: Addressing Machining's Talent Gap

      Skilled machinists must be cultivated through education and apprenticeships to gain complete knowledge of their tools and craft.
      Sam Brusco, Associate Editor 01.30.19

    • Contract Manufacturing
      Deciphering Dosage: A Focus on Combination Products

      Deciphering Dosage: A Focus on Combination Products

      Manufacturing novel drug delivery/combination devices requires partnerships between previously unlikely pairings of companies
      Sam Brusco, Associate Editor 11.26.18


    • Contract Manufacturing
      Automating the Manufacturing Orchestra

      Automating the Manufacturing Orchestra

      Sophisticated welding tools, robotic systems, DFM, and Industry 4.0 address medtech assembly challenges.
      Mark Crawford, Contributing Writer 10.16.18

    • Electronics
      Driving Toward Custom Electronics

      Driving Toward Custom Electronics

      Off-the-shelf options can be adapted to suit needs, but more device makers are looking at custom electronic solutions.
      Mark Crawford, Contributing Writer 09.07.18

    • Contract Manufacturing | Machining & Laser Processing | Molding | Packaging & Sterilization | R&D & Design | Testing | Tubing & Extrusion
      Addressing Peak Issues in Medtech

      Addressing Peak Issues in Medtech

      The 2018 MPO Summit heads to Colorado for discussion, education, and networking.
      Sean Fenske, Editor-in-Chief 07.26.18


    Trending
    • Masimo Earns CE Mark For New Fingertip Pulse Oximeter
    • Portable, Home-Use Device Quickly Measures Inflammation Levels
    • Understanding Food-Grade Vs. Biocompatibility For Medical Device Materials
    • Telemedicine, Regulatory Changes To Characterize Medtech Industry In 2021
    • Medtech Matters: Surgeons Scrubbing In Virtually
    Breaking News
    • Cretex Companies CEO Steps Down
    • Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    • Endoscopic Hemostasis Devices Market Valued at $730 Million
    • Henry Schein Buys Majority Interest in Prism Medical Products
    • Boston Scientific's Vercise Genus DBS Earns FDA Approval
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Pharmaceutical Focus: A Look at Combination Products
    • The Printed World: Additive Manufacturing in Medtech
    • The Lost Year: 2020 Year in Review
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login